Related Content
Search Google Scholar for:
|
Published Online March 11, 2004 Science
DOI: 10.1126/science.1096502
|
|
Brevia
Submitted on February 6, 2004
Accepted on February 27, 2004
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Yardena Samuels 1,
Zhenghe Wang 1,
Alberto Bardelli 1,
Natalie Silliman 1,
Janine Ptak 1,
Steve Szabo 1,
Hai Yan 2,
Adi Gazdar 3,
Steven M. Powell 4,
Gregory J. Riggins 1,
James K.V. Willson 5,
Sanford Markowitz 5,
Kenneth W. Kinzler 1,
Bert Vogelstein 1,
Victor E. Velculescu 1*
1 The Sidney Kimmel Comprehensive Cancer Center and The Howard Hughes Medical Institute, The Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA.
2 Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
3 Hamon Center for Therapeutic Oncology Research and Dept. of Pathology, UT Southwestern Medical Center, Dallas TX 75390, USA.
4 Division of Gastroenterology/Hepatology, UVA Health System, Charlottesville, VA 22908, USA.
5 Howard Hughes Medical Institute and Ireland Cancer Center, University Hospitals of Cleveland and Case Western University, Cleveland, OH 44106, USA.
* To whom correspondence should be addressed. E-mail: velculescu{at}jhmi.edu.
A gene coding for a well-known lipid kinase is frequently mutated in human tumors, offering a new target for cancer diagnosis and therapy.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
- Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab.
- E. Yao, W. Zhou, S. T. Lee-Hoeflich, T. Truong, P. M. Haverty, J. Eastham-Anderson, N. Lewin-Koh, B. Gunter, M. Belvin, L. J. Murray, et al. (2009)
Clin. Cancer Res.
15, 4147-4156
| Abstract »
| Full Text »
| PDF »
- Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma.
- B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al. (2009)
Ann. Onc.
| Abstract »
| Full Text »
| PDF »
- Pathogenesis of lung cancer signalling pathways: roadmap for therapies.
- E. Brambilla and A. Gazdar (2009)
Eur. Respir. J.
33, 1485-1497
| Abstract »
| Full Text »
| PDF »
- Are We Hitting the Right Combination for Hormonally Sensitive Breast Cancer?.
- D. Tripathy (2009)
J. Clin. Oncol.
27, 2580-2582
| Full Text »
| PDF »
- Blocking Phosphoinositide 3-Kinase Activity in Colorectal Cancer Cells Reduces Proliferation but Does Not Increase Apoptosis Alone or in Combination with Cytotoxic Drugs.
- C. Martin-Fernandez, J. Bales, C. Hodgkinson, A. Welman, M. J. Welham, C. Dive, and C. J. Morrow (2009)
Mol. Cancer Res.
7, 955-965
| Abstract »
| Full Text »
| PDF »
- PIK3CA and PIK3CB Inhibition Produce Synthetic Lethality when Combined with Estrogen Deprivation in Estrogen Receptor-Positive Breast Cancer.
- R. J. Crowder, C. Phommaly, Y. Tao, J. Hoog, J. Luo, C. M. Perou, J. S. Parker, M. A. Miller, D. G. Huntsman, L. Lin, et al. (2009)
Cancer Res.
69, 3955-3962
| Abstract »
| Full Text »
| PDF »
- Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma.
- K.-T. Kuo, T.-L. Mao, S. Jones, E. Veras, A. Ayhan, T.-L. Wang, R. Glas, D. Slamon, V. E. Velculescu, R. J. Kuman, et al. (2009)
Am. J. Pathol.
174, 1597-1601
| Abstract »
| Full Text »
| PDF »
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer.
- H. Prenen, J. De Schutter, B. Jacobs, W. De Roock, B. Biesmans, B. Claes, D. Lambrechts, E. Van Cutsem, and S. Tejpar (2009)
Clin. Cancer Res.
15, 3184-3188
| Abstract »
| Full Text »
| PDF »
- Knockdown of Ron Kinase Inhibits Mutant Phosphatidylinositol 3-Kinase and Reduces Metastasis in Human Colon Carcinoma.
- J. Wang, A. Rajput, J. L. C. Kan, R. Rose, X.-Q. Liu, K. Kuropatwinski, J. Hauser, A. Beko, I. Dominquez, E. A. Sharratt, et al. (2009)
J. Biol. Chem.
284, 10912-10922
| Abstract »
| Full Text »
| PDF »
- Gene Expression Patterns in Mismatch Repair-Deficient Colorectal Cancers Highlight the Potential Therapeutic Role of Inhibitors of the Phosphatidylinositol 3-Kinase-AKT-Mammalian Target of Rapamycin Pathway.
- E. Vilar, B. Mukherjee, R. Kuick, L. Raskin, D. E. Misek, J. M.G. Taylor, T. J. Giordano, S. M. Hanash, E. R. Fearon, G. Rennert, et al. (2009)
Clin. Cancer Res.
15, 2829-2839
| Abstract »
| Full Text »
| PDF »
- KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.
- J. J. Yeh, E. D. Routh, T. Rubinas, J. Peacock, T. D. Martin, X. J. Shen, R. S. Sandler, H. J. Kim, T. O. Keku, and C. J. Der (2009)
Mol. Cancer Ther.
8, 834-843
| Abstract »
| Full Text »
| PDF »
- PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer.
- S. Ogino, K. Nosho, G. J. Kirkner, K. Shima, N. Irahara, S. Kure, A. T. Chan, J. A. Engelman, P. Kraft, L. C. Cantley, et al. (2009)
J. Clin. Oncol.
27, 1477-1484
| Abstract »
| Full Text »
| PDF »
- Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors.
- Y. Lin, X. Jiang, Y. Shen, M. Li, H. Ma, M. Xing, and Y. Lu (2009)
Endocr. Relat. Cancer
16, 301-310
| Abstract »
| Full Text »
| PDF »
- Tumor suppressors and cell metabolism: a recipe for cancer growth.
- R. G. Jones and C. B. Thompson (2009)
Genes & Dev.
23, 537-548
| Abstract »
| Full Text »
| PDF »
- The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
- A. Greenhough, H. J.M. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi (2009)
Carcinogenesis
30, 377-386
| Abstract »
| Full Text »
| PDF »
- Molecular determinants of response to matuzumab in combination with paclitaxel for patients with advanced non-small cell lung cancer.
- M. M. Schittenhelm, C. Kollmannsberger, K. Oechsle, A. Harlow, J. Morich, F. Honecker, R. Kurek, S. Storkel, L. Kanz, C. L. Corless, et al. (2009)
Mol. Cancer Ther.
8, 481-489
| Abstract »
| Full Text »
| PDF »
- Knockin of mutant PIK3CA activates multiple oncogenic pathways.
- J. P. Gustin, B. Karakas, M. B. Weiss, A. M. Abukhdeir, J. Lauring, J. P. Garay, D. Cosgrove, A. Tamaki, H. Konishi, Y. Konishi, et al. (2009)
PNAS
106, 2835-2840
| Abstract »
| Full Text »
| PDF »
- Mutations and Response to Epidermal Growth Factor Receptor Inhibitors.
- P. Laurent-Puig, A. Lievre, and H. Blons (2009)
Clin. Cancer Res.
15, 1133-1139
| Abstract »
| Full Text »
| PDF »
- Marked Activity of Irinotecan and Rapamycin Combination toward Colon Cancer Cells In vivo and In vitro Is Mediated through Cooperative Modulation of the Mammalian Target of Rapamycin/Hypoxia-Inducible Factor-1{alpha} Axis.
- E. Pencreach, E. Guerin, C. Nicolet, I. Lelong-Rebel, A.-C. Voegeli, P. Oudet, A. K. Larsen, M.-P. Gaub, and D. Guenot (2009)
Clin. Cancer Res.
15, 1297-1307
| Abstract »
| Full Text »
| PDF »
- Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells.
- G. L. Gallia, B. M. Tyler, C. L. Hann, I-M. Siu, V. L. Giranda, A. L. Vescovi, H. Brem, and G. J. Riggins (2009)
Mol. Cancer Ther.
8, 386-393
| Abstract »
| Full Text »
| PDF »
- Human T-cell Leukemia Virus Type I Tax Down-regulates the Expression of Phosphatidylinositol 3,4,5-Trisphosphate Inositol Phosphatases via the NF-{kappa}B Pathway.
- R.-i. Fukuda, K. Tsuchiya, K. Suzuki, K. Itoh, J. Fujita, A. Utsunomiya, and T. Tsuji (2009)
J. Biol. Chem.
284, 2680-2689
| Abstract »
| Full Text »
| PDF »
- Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition.
- O. K. Mirzoeva, D. Das, L. M. Heiser, S. Bhattacharya, D. Siwak, R. Gendelman, N. Bayani, N. J. Wang, R. M. Neve, Y. Guan, et al. (2009)
Cancer Res.
69, 565-572
| Abstract »
| Full Text »
| PDF »
- Inhibition of mTOR Radiosensitizes Soft Tissue Sarcoma and Tumor Vasculature.
- J. D. Murphy, A. C. Spalding, Y. R. Somnay, S. Markwart, M. E. Ray, and D. A. Hamstra (2009)
Clin. Cancer Res.
15, 589-596
| Abstract »
| Full Text »
| PDF »
- Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma.
- A. Broniscer, S. J. Baker, C. F. Stewart, T. E. Merchant, F. H. Laningham, P. Schaiquevich, M. Kocak, E. B. Morris, R. Endersby, D. W. Ellison, et al. (2009)
Clin. Cancer Res.
15, 701-707
| Abstract »
| Full Text »
| PDF »
- Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy.
- N. T. Ihle and G. Powis (2009)
Mol. Cancer Ther.
8, 1-9
| Abstract »
| Full Text »
| PDF »
- Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells.
- C. M.-E. Sauvageot, J. L. Weatherbee, S. Kesari, S. E. Winters, J. Barnes, J. Dellagatta, N. R. Ramakrishna, C. D. Stiles, A. L.-J. Kung, M. W. Kieran, et al. (2009)
Neuro-oncol
11, 109-121
| Abstract »
| Full Text »
| PDF »
- Irs2 Inactivation Suppresses Tumor Progression in Pten+/- Mice.
- M. Szabolcs, M. Keniry, L. Simpson, L. J. Reid, S. Koujak, S. C. Schiff, G. Davidian, S. Licata, S. Gruvberger-Saal, V. V.V.S. Murty, et al. (2009)
Am. J. Pathol.
174, 276-286
| Abstract »
| Full Text »
| PDF »
- Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.
- E. A. Papakonstanti, O. Zwaenepoel, A. Bilancio, E. Burns, G. E. Nock, B. Houseman, K. Shokat, A. J. Ridley, and B. Vanhaesebroeck (2008)
J. Cell Sci.
121, 4124-4133
| Abstract »
| Full Text »
| PDF »
- Unbiased Screening for Transcriptional Targets of ZKSCAN3 Identifies Integrin {beta}4 and Vascular Endothelial Growth Factor as Downstream Targets.
- L. Yang, L. Zhang, Q. Wu, and D. D. Boyd (2008)
J. Biol. Chem.
283, 35295-35304
| Abstract »
| Full Text »
| PDF »
- Activation of Phosphatidylinositol 3-Kinase by Membrane Localization of p110{alpha} Predisposes Mammary Glands to Neoplastic Transformation.
- O. Renner, C. Blanco-Aparicio, M. Grassow, M. Canamero, J. F.M. Leal, and A. Carnero (2008)
Cancer Res.
68, 9643-9653
| Abstract »
| Full Text »
| PDF »
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235.
- P. J.A. Eichhorn, M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, et al. (2008)
Cancer Res.
68, 9221-9230
| Abstract »
| Full Text »
| PDF »
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations.
- V. Serra, B. Markman, M. Scaltriti, P. J.A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, et al. (2008)
Cancer Res.
68, 8022-8030
| Abstract »
| Full Text »
| PDF »
- PIK3CA Cooperates with Other Phosphatidylinositol 3'-Kinase Pathway Mutations to Effect Oncogenic Transformation.
- K. Oda, J. Okada, L. Timmerman, P. Rodriguez-Viciana, D. Stokoe, K. Shoji, Y. Taketani, H. Kuramoto, Z. A. Knight, K. M. Shokat, et al. (2008)
Cancer Res.
68, 8127-8136
| Abstract »
| Full Text »
| PDF »
- The Forkhead Transcription Factor FOXO3a Increases Phosphoinositide-3 Kinase/Akt Activity in Drug-Resistant Leukemic Cells through Induction of PIK3CA Expression.
- R. C.-Y. Hui, A. R. Gomes, D. Constantinidou, J. R. Costa, C. T. Karadedou, S. Fernandez de Mattos, M. P. Wymann, J. J. Brosens, A. Schulze, and E. W.-F. Lam (2008)
Mol. Cell. Biol.
28, 5886-5898
| Abstract »
| Full Text »
| PDF »
- A High-Throughput Liposome Substrate Assay with Automated Lipid Extraction Process for PI 3-Kinase.
- T. Lingaraj, J. Donovan, Z. Li, P. Li, A. Doucette, S. Harrison, J. A. Ecsedy, L. Dang, and W. Zhang (2008)
J Biomol Screen
13, 906-911
| Abstract »
| PDF »
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme.
- D. W. Parsons, S. Jones, X. Zhang, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, I-M. Siu, G. L. Gallia, et al. (2008)
Science
321, 1807-1812
| Abstract »
| Full Text »
| PDF »
- LKB1 Is Necessary for Akt-Mediated Phosphorylation of Proapoptotic Proteins.
- D. Zhong, X. Liu, F. R. Khuri, S.-Y. Sun, P. M. Vertino, and W. Zhou (2008)
Cancer Res.
68, 7270-7277
| Abstract »
| Full Text »
| PDF »
- PTEN-deficient cancers depend on PIK3CB.
- S. Wee, D. Wiederschain, S.-M. Maira, A. Loo, C. Miller, R. deBeaumont, F. Stegmeier, Y.-M. Yao, and C. Lengauer (2008)
PNAS
105, 13057-13062
| Abstract »
| Full Text »
| PDF »
- PIK3CA Mutations and Copy Number Gains in Human Lung Cancers.
- H. Yamamoto, H. Shigematsu, M. Nomura, W. W. Lockwood, M. Sato, N. Okumura, J. Soh, M. Suzuki, I. I. Wistuba, K. M. Fong, et al. (2008)
Cancer Res.
68, 6913-6921
| Abstract »
| Full Text »
| PDF »
- An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer.
- K. Stemke-Hale, A. M. Gonzalez-Angulo, A. Lluch, R. M. Neve, W.-L. Kuo, M. Davies, M. Carey, Z. Hu, Y. Guan, A. Sahin, et al. (2008)
Cancer Res.
68, 6084-6091
| Abstract »
| Full Text »
| PDF »
- PIK3IP1, a Negative Regulator of PI3K, Suppresses the Development of Hepatocellular Carcinoma.
- X. He, Z. Zhu, C. Johnson, J. Stoops, A. E. Eaker, W. Bowen, and M. C. DeFrances (2008)
Cancer Res.
68, 5591-5598
| Abstract »
| Full Text »
| PDF »
- Class I PI3 Kinase Inhibition by the Pyridinylfuranopyrimidine Inhibitor PI-103 Enhances Tumor Radiosensitivity.
- R. Prevo, E. Deutsch, O. Sampson, J. Diplexcito, K. Cengel, J. Harper, P. O'Neill, W. G. McKenna, S. Patel, and E. J. Bernhard (2008)
Cancer Res.
68, 5915-5923
| Abstract »
| Full Text »
| PDF »
- Class 1A PI3K regulates vessel integrity during development and tumorigenesis.
- T. L. Yuan, H. S. Choi, A. Matsui, C. Benes, E. Lifshits, J. Luo, J. V. Frangioni, and L. C. Cantley (2008)
PNAS
105, 9739-9744
| Abstract »
| Full Text »
| PDF »
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity.
- S.-M. Maira, F. Stauffer, J. Brueggen, P. Furet, C. Schnell, C. Fritsch, S. Brachmann, P. Chene, A. De Pover, K. Schoemaker, et al. (2008)
Mol. Cancer Ther.
7, 1851-1863
| Abstract »
| Full Text »
| PDF »
- Defining the blueprint of the cancer genome.
- V. E. Velculescu (2008)
Carcinogenesis
29, 1087-1091
| Abstract »
| Full Text »
| PDF »
- Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer.
- A. Jimeno, A. C. Tan, J. Coffa, N.V. Rajeshkumar, P. Kulesza, B. Rubio-Viqueira, J. Wheelhouse, B. Diosdado, W. A. Messersmith, C. Iacobuzio-Donahue, et al. (2008)
Cancer Res.
68, 2841-2849
| Abstract »
| Full Text »
| PDF »
- The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy.
- M. Scaltriti and J. Baselga (2008)
Am. Assoc. Cancer Res. Educ. Book
2008, 91-98
| Abstract »
| Full Text »
| PDF »
- PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients.
- Y.-L. Lai, B.-L. Mau, W.-H. Cheng, H.-M. Chen, H.-H. Chiu, and C.-Y. Tzen (2008)
Ann. Surg. Oncol.
15, 1064-1069
| Abstract »
| Full Text »
| PDF »
- Multiplexed Assays for Detection of Mutations in PIK3CA.
- R. E. Board, N. J. Thelwell, P. F. Ravetto, S. Little, M. Ranson, C. Dive, A. Hughes, and D. Whitcombe (2008)
Clin. Chem.
54, 757-760
| Abstract »
| Full Text »
| PDF »
- PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab.
- M. Jhawer, S. Goel, A. J. Wilson, C. Montagna, Y.-H. Ling, D.-S. Byun, S. Nasser, D. Arango, J. Shin, L. Klampfer, et al. (2008)
Cancer Res.
68, 1953-1961
| Abstract »
| Full Text »
| PDF »
- Conditional Deletion of Pten Causes Bronchiolar Hyperplasia.
- V. Dave, S. E. Wert, T. Tanner, A. R. Thitoff, D. E. Loudy, and J. A. Whitsett (2008)
Am. J. Respir. Cell Mol. Biol.
38, 337-345
| Abstract »
| Full Text »
| PDF »
- Helical domain and kinase domain mutations in p110{alpha} of phosphatidylinositol 3-kinase induce gain of function by different mechanisms.
- L. Zhao and P. K. Vogt (2008)
PNAS
105, 2652-2657
| Abstract »
| Full Text »
| PDF »
- Association between Phosphatidylinositol 3-Kinase Regulatory Subunit p85{alpha} Met326Ile Genetic Polymorphism and Colon Cancer Risk.
- L. Li, S. J. Plummer, C. L. Thompson, T. C. Tucker, and G. Casey (2008)
Clin. Cancer Res.
14, 633-637
| Abstract »
| Full Text »
| PDF »
- t-Darpp Promotes Cancer Cell Survival by Up-regulation of Bcl2 through Akt-Dependent Mechanism.
- A. Belkhiri, A. A. Dar, A. Zaika, M. Kelley, and W. El-Rifai (2008)
Cancer Res.
68, 395-403
| Abstract »
| Full Text »
| PDF »
- Phase I Pharmacokinetic/Pharmacodynamic Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Combination with Irinotecan, 5-Fluorouracil, and Leucovorin (FOLFIRI) in First-Line Treatment of Patients with Metastatic Colorectal Cancer.
- G. Folprecht, J. Tabernero, C.-H. Kohne, C. Zacharchuk, L. Paz-Ares, F. Rojo, S. Quinn, E. Casado, R. Salazar, R. Abbas, et al. (2008)
Clin. Cancer Res.
14, 215-223
| Abstract »
| Full Text »
| PDF »
- DNA Damage-Induced Acetylation of Lysine 3016 of ATM Activates ATM Kinase Activity.
- Y. Sun, Y. Xu, K. Roy, and B. D. Price (2007)
Mol. Cell. Biol.
27, 8502-8509
| Abstract »
| Full Text »
| PDF »
- The Structure of a Human p110{alpha}/p85{alpha} Complex Elucidates the Effects of Oncogenic PI3K{alpha} Mutations.
- C.-H. Huang, D. Mandelker, O. Schmidt-Kittler, Y. Samuels, V. E. Velculescu, K. W. Kinzler, B. Vogelstein, S. B. Gabelli, and L. M. Amzel (2007)
Science
318, 1744-1748
| Abstract »
| Full Text »
| PDF »
- Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression.
- M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid (2007)
Cancer Res.
67, 11300-11308
| Abstract »
| Full Text »
| PDF »
- Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin.
- J. Shao, M.K. Washington, R. Saxena, and H. Sheng (2007)
Carcinogenesis
28, 2476-2483
| Abstract »
| Full Text »
| PDF »
- The Genomic Landscapes of Human Breast and Colorectal Cancers.
- L. D. Wood, D. W. Parsons, S. Jones, J. Lin, T. Sjoblom, R. J. Leary, D. Shen, S. M. Boca, T. Barber, J. Ptak, et al. (2007)
Science
318, 1108-1113
| Abstract »
| Full Text »
| PDF »
- Common and Distinct Genomic Events in Sporadic Colorectal Cancer and Diverse Cancer Types.
- E. S. Martin, G. Tonon, R. Sinha, Y. Xiao, B. Feng, A. C. Kimmelman, A. Protopopov, E. Ivanova, C. Brennan, K. Montgomery, et al. (2007)
Cancer Res.
67, 10736-10743
| Abstract »
| Full Text »
| PDF »
- Malignant astrocytic glioma: genetics, biology, and paths to treatment.
- F. B. Furnari, T. Fenton, R. M. Bachoo, A. Mukasa, J. M. Stommel, A. Stegh, W. C. Hahn, K. L. Ligon, D. N. Louis, C. Brennan, et al. (2007)
Genes & Dev.
21, 2683-2710
| Abstract »
| Full Text »
| PDF »
- Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics.
- L.-Y. Choong, S. Lim, M. C.-S. Loh, X. Man, Y. Chen, W. Toy, M. Pan, C.-S. Chen, A. Poonepalli, M. P. Hande, et al. (2007)
Mol. Cancer Ther.
6, 2828-2842
| Abstract »
| Full Text »
| PDF »
- Phase I Study of Everolimus in Pediatric Patients With Refractory Solid Tumors.
- M. Fouladi, F. Laningham, J. Wu, M. A. O'Shaughnessy, K. Molina, A. Broniscer, S. L. Spunt, I. Luckett, C. F. Stewart, P. J. Houghton, et al. (2007)
J. Clin. Oncol.
25, 4806-4812
| Abstract »
| Full Text »
| PDF »
- In vivo Functional Analysis of the Counterbalance of Hyperactive Phosphatidylinositol 3-Kinase p110 Catalytic Oncoproteins by the Tumor Suppressor PTEN.
- A. Andres-Pons, I. Rodriguez-Escudero, A. Gil, A. Blanco, A. Vega, M. Molina, R. Pulido, and V. J. Cid (2007)
Cancer Res.
67, 9731-9739
| Abstract »
| Full Text »
| PDF »
- Different Prognostic Roles of Mutations in the Helical and Kinase Domains of the PIK3CA Gene in Breast Carcinomas.
- M. Barbareschi, F. Buttitta, L. Felicioni, S. Cotrupi, F. Barassi, M. Del Grammastro, A. Ferro, P. Dalla Palma, E. Galligioni, and A. Marchetti (2007)
Clin. Cancer Res.
13, 6064-6069
| Abstract »
| Full Text »
| PDF »
- p66 Shc Tumor Levels Show a Strong Prognostic Correlation with Disease Outcome in Stage IIA Colon Cancer.
- S. R. Grossman, S. Lyle, M. B. Resnick, E. Sabo, R. T. Lis, E. Rosinha, Q. Liu, C.-C. Hsieh, G. Bhat, A. R. Frackelton Jr., et al. (2007)
Clin. Cancer Res.
13, 5798-5804
| Abstract »
| Full Text »
| PDF »
- Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.
- N. Kawamata, J. Chen, and H. P. Koeffler (2007)
Blood
110, 2667-2673
| Abstract »
| Full Text »
| PDF »
- Integrative Genomic Analysis of Phosphatidylinositol 3'-Kinase Family Identifies PIK3R3 as a Potential Therapeutic Target in Epithelial Ovarian Cancer.
- L. Zhang, J. Huang, N. Yang, J. Greshock, S. Liang, K. Hasegawa, A. Giannakakis, N. Poulos, A. O'Brien-Jenkins, D. Katsaros, et al. (2007)
Clin. Cancer Res.
13, 5314-5321
| Abstract »
| Full Text »
| PDF »
- The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.
- A. L. Howes, G. G. Chiang, E. S. Lang, C. B. Ho, G. Powis, K. Vuori, and R. T. Abraham (2007)
Mol. Cancer Ther.
6, 2505-2514
| Abstract »
| Full Text »
| PDF »
- Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-{alpha}]isoquinolin-4-one.
- L. M. Ballou, E. S. Selinger, J. Y. Choi, D. G. Drueckhammer, and R. Z. Lin (2007)
J. Biol. Chem.
282, 24463-24470
| Abstract »
| Full Text »
| PDF »
- Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern.
- C. Hafner, E. Lopez-Knowles, N. M. Luis, A. Toll, E. Baselga, A. Fernandez-Casado, S. Hernandez, A. Ribe, T. Mentzel, R. Stoehr, et al. (2007)
PNAS
104, 13450-13454
| Abstract »
| Full Text »
| PDF »
- The Role of Phosphoinositide 3-Kinase Pathway Inhibitors in the Treatment of Lung Cancer.
- J. A. Engelman (2007)
Clin. Cancer Res.
13, 4637s-4640s
| Abstract »
| Full Text »
| PDF »
- Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit.
- N. Miled, Y. Yan, W.-C. Hon, O. Perisic, M. Zvelebil, Y. Inbar, D. Schneidman-Duhovny, H. J. Wolfson, J. M. Backer, and R. L. Williams (2007)
Science
317, 239-242
| Abstract »
| Full Text »
| PDF »
- The p110{alpha} Isoform of Phosphatidylinositol 3-Kinase Is Essential for Polyomavirus Middle T Antigen-Mediated Transformation.
- T. Utermark, B. S. Schaffhausen, T. M. Roberts, and J. J. Zhao (2007)
J. Virol.
81, 7069-7076
| Abstract »
| Full Text »
| PDF »
- Mucinous Differentiation Correlates with Absence of EGFR Mutation and Presence of KRAS Mutation in Lung Adenocarcinomas with Bronchioloalveolar Features.
- K. E. Finberg, L. V. Sequist, V. A. Joshi, A. Muzikansky, J. M. Miller, M. Han, J. Beheshti, L. R. Chirieac, E. J. Mark, and A. J. Iafrate (2007)
J. Mol. Diagn.
9, 320-326
| Abstract »
| Full Text »
| PDF »
- PTEN, more than the AKT pathway.
- C. Blanco-Aparicio, O. Renner, J. F.M. Leal, and A. Carnero (2007)
Carcinogenesis
28, 1379-1386
| Abstract »
| Full Text »
| PDF »
- Cancer genomics: integrating form and function.
- S. Y. Kim and W. C. Hahn (2007)
Carcinogenesis
28, 1387-1392
| Abstract »
| Full Text »
| PDF »
- Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases.
- F. I. Raynaud, S. Eccles, P. A. Clarke, A. Hayes, B. Nutley, S. Alix, A. Henley, F. Di-Stefano, Z. Ahmad, S. Guillard, et al. (2007)
Cancer Res.
67, 5840-5850
| Abstract »
| Full Text »
| PDF »
- Mutant PIK3CA-Bearing Colon Cancer Cells Display Increased Metastasis in an Orthotopic Model.
- X.-N. Guo, A. Rajput, R. Rose, J. Hauser, A. Beko, K. Kuropatwinski, C. LeVea, R. M. Hoffman, M. G. Brattain, and J. Wang (2007)
Cancer Res.
67, 5851-5858
| Abstract »
| Full Text »
| PDF »
- PIK3CA Mutations and PTEN Loss Correlate with Similar Prognostic Factors and Are Not Mutually Exclusive in Breast Cancer.
- G. Perez-Tenorio, L. Alkhori, B. Olsson, M. A. Waltersson, B. Nordenskjold, L. E. Rutqvist, L. Skoog, and O. Stal (2007)
Clin. Cancer Res.
13, 3577-3584
| Abstract »
| Full Text »
| PDF »
- Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers.
- K. Nosho, H. Yamamoto, T. Takahashi, M. Mikami, H. Taniguchi, N. Miyamoto, Y. Adachi, Y. Arimura, F. Itoh, K. Imai, et al. (2007)
Carcinogenesis
28, 1364-1370
| Abstract »
| Full Text »
| PDF »
- A New Crucial Protein Interaction Element That Targets the Adenovirus E4-ORF1 Oncoprotein to Membrane Vesicles.
- S.-H. Chung, K. K. Frese, R. S. Weiss, B. V. V. Prasad, and R. T. Javier (2007)
J. Virol.
81, 4787-4797
| Abstract »
| Full Text »
| PDF »
- Rare cancer-specific mutations in PIK3CA show gain of function.
- M. Gymnopoulos, M.-A. Elsliger, and P. K. Vogt (2007)
PNAS
104, 5569-5574
| Abstract »
| Full Text »
| PDF »
- Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.
- J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al. (2007)
Mol. Cancer Ther.
6, 1143-1150
| Abstract »
| Full Text »
| PDF »
- Clinical and Molecular Characteristics of Malignant Transformation of Low-Grade Glioma in Children.
- A. Broniscer, S. J. Baker, A. N. West, M. M. Fraser, E. Proko, M. Kocak, J. Dalton, G. P. Zambetti, D. W. Ellison, L. E. Kun, et al. (2007)
J. Clin. Oncol.
25, 682-689
| Abstract »
| Full Text »
| PDF »
- Lung premalignancy induced by mutant B-Raf, what is thy fate? To senesce or not to senesce, that is the question.
- K. M. Haigis, I. I. Wistuba, and J. M. Kurie (2007)
Genes & Dev.
21, 361-366
| Full Text »
| PDF »
- Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer.
- P. Hou, D. Liu, Y. Shan, S. Hu, K. Studeman, S. Condouris, Y. Wang, A. Trink, A. K. El-Naggar, G. Tallini, et al. (2007)
Clin. Cancer Res.
13, 1161-1170
| Abstract »
| Full Text »
| PDF »
- Mitogen-activated Protein Kinase Kinase-4 Promotes Cell Survival by Decreasing PTEN Expression through an NF{kappa}B-dependent Pathway.
- D. Xia, H. Srinivas, Y.-h. Ahn, G. Sethi, X. Sheng, W. K. A. Yung, Q. Xia, P. J. Chiao, H. Kim, P. H. Brown, et al. (2007)
J. Biol. Chem.
282, 3507-3519
| Abstract »
| Full Text »
| PDF »
- Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines.
- A. Hollestelle, F. Elstrodt, J. H.A. Nagel, W. W. Kallemeijn, and M. Schutte (2007)
Mol. Cancer Res.
5, 195-201
| Abstract »
| Full Text »
| PDF »
- Combination of sublethal concentrations of epidermal growth factor receptor inhibitor and microtubule stabilizer induces apoptosis of glioblastoma cells.
- M. Failly, S. Korur, V. Egler, J.-L. Boulay, M. M. Lino, R. Imber, and A. Merlo (2007)
Mol. Cancer Ther.
6, 773-781
| Abstract »
| Full Text »
| PDF »
- Distinguishing Cancer-Associated Missense Mutations from Common Polymorphisms.
- J. S. Kaminker, Y. Zhang, A. Waugh, P. M. Haverty, B. Peters, D. Sebisanovic, J. Stinson, W. F. Forrest, J. F. Bazan, S. Seshagiri, et al. (2007)
Cancer Res.
67, 465-473
| Abstract »
| Full Text »
| PDF »
- Activation of Akt Predicts Poor Outcome in Neuroblastoma.
- D. Opel, C. Poremba, T. Simon, K.-M. Debatin, and S. Fulda (2007)
Cancer Res.
67, 735-745
| Abstract »
| Full Text »
| PDF »
- Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA.
- J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman (2007)
Mol. Cell. Biol.
27, 662-677
| Abstract »
| Full Text »
| PDF »
- Clinicopathologic Analysis of Breast Cancers with PIK3CA Mutations in Japanese Women.
- N. Maruyama, Y. Miyoshi, T. Taguchi, Y. Tamaki, M. Monden, and S. Noguchi (2007)
Clin. Cancer Res.
13, 408-414
| Abstract »
| Full Text »
| PDF »
- PI3 Kinases in Cancer: From Oncogene Artifact to Leading Cancer Target.
- J. J. Zhao and T. M. Roberts (2006)
Sci. STKE
2006, pe52
| Abstract »
| Full Text »
| PDF »
- Phosphatidylinositol 3-Kinase-dependent Modulation of Carnitine Palmitoyltransferase 1A Expression Regulates Lipid Metabolism during Hematopoietic Cell Growth.
- R. J. DeBerardinis, J. J. Lum, and C. B. Thompson (2006)
J. Biol. Chem.
281, 37372-37380
| Abstract »
| Full Text »
| PDF »
- Improved Marker Combination for Detection of De Novo Genetic Variation and Aberrant DNA in Colorectal Neoplasia.
- L. Kann, J. Han, D. Ahlquist, T. Levin, D. Rex, D. Whitney, S. Markowitz, and A. Shuber (2006)
Clin. Chem.
52, 2299-2302
| Abstract »
| Full Text »
| PDF »
- PIK3CA and PTEN Mutations in Uterine Endometrioid Carcinoma and Complex Atypical Hyperplasia..
- M. P. Hayes, H. Wang, R. Espinal-Witter, W. Douglas, G. J. Solomon, S. J. Baker, and L. H. Ellenson (2006)
Clin. Cancer Res.
12, 5932-5935
| Abstract »
| Full Text »
| PDF »
- PIK3CA Gene Mutations in Pediatric and Adult Glioblastoma Multiforme.
- G. L. Gallia, V. Rand, I-M. Siu, C. G. Eberhart, C. D. James, S. K.N. Marie, S. M. Oba-Shinjo, C. G. Carlotti, O. L. Caballero, A. J.G. Simpson, et al. (2006)
Mol. Cancer Res.
4, 709-714
| Abstract »
| Full Text »
| PDF »
|
|